Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet global vaccine manufacturing requirements. Additionally, the pharma services business has been providing pharma and biotech customers with the services they need to develop and produce vaccines and therapies globally. Thermo Fisher's business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augmen ...

Thermo Fisher Scientific (TMO) recently introduced the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators to support the future implementation of workflow automation in cell therapy production. These first-of-their-kind CO2 incubators are designed for integration into automated and modular laboratories. The latest development from Thermo Fisher represents the most advanced incubators in the VIOS portfolio. The company's VIOS family of incubators is known for optimal cell growth conditions and minimal c ...

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments The report analyzes all pipeline products in development for the company Thermo Fisher Scientific Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) The report covers detailed informatio ...

through a tough time that might impact their academic budgets. Thermo Fisher remains cautious since growth could further moderate if the economic scenario worsens. The Zacks Consensus Estimate for 2024 earnings per share (EPS) has moved to $21.65 from $21.64 in the past 30 days. Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS) , Medpace (MEDP) and ResMed (RMD) . Medpace, also sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of 27.1% compared ...

narvikk Introduction On April 24, I wrote an article covering Alexandria Real Estate Equities (ARE), a REIT that owns healthcare real estate, including laboratories. This REIT is on my radar as a fantastic way to benefit from innovation in healthcare without having to figure out which biotech company will reveal a groundbreaking drug next. [...] the company has provided the facilities that allowed for groundbreaking research, as the company noted that roughly half of all FDA-approved therapies over the past ...

VANCOUVER, BC, May 23, 2024 /PRNewswire/ - Trilogy Metals Inc. (TSX: TMO) (NYSE American: TMQ) ("Trilogy Metals" or the "Company") is pleased to announce the detailed voting results on the items of business considered at its Annual Meeting of Shareholders ("Meeting") held in Vancouver on Wednesday, May 22, 2024. All proposals were approved and the nominees listed in the management proxy circular for the meeting were all elected as directors. A total of 98,964,326 or 61.79% of the Company's issued and outsta ...

Thermo Fisher Scientific (TMO) recently introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research. The new array detects most extended and rare blood groups, tissue (HLA) and platelet (HPA) types in a single, highthroughput assay, supporting future advancements in donor blood matching for extended phenotypes. The latest development is expected to enhance the company's Life Sciences Solutions segment, which off ...

Summary of Thermo Fisher Scientific Inc. Conference Call Company Overview - **Company**: Thermo Fisher Scientific Inc. (NYSE:TMO) - **Event**: Bank of America Securities 2024 Health Care Conference Call - **Date**: May 14, 2024 - **Participants**: Marc Casper (CEO), Mike Ryskin (Bank of America) Industry Insights - **Long-term Industry Growth**: The industry is experiencing strong long-term growth driven by drug pipelines, scientific discoveries, unmet healthcare needs, and advances in technologies such as semiconductors and batteries [4][5] - **Short-term Market Conditions**: The first quarter of 2024 met expectations with predictability in markets. Economic activity is expected to improve modestly throughout the year, supported by China's stimulus program and increased biotech funding [4][5] - **China's Economic Impact**: China is seen as a significant growth market, although growth rates are expected to be lower than in the past decade. A multiyear fiscal stimulus program focused on capital equipment is anticipated to benefit Thermo Fisher's Analytical Instruments segment [10][11][12] Financial Performance and Projections - **2024 Outlook**: The company raised its outlook for the year, expecting modest market improvements and a stronger second half compared to the first half. The guidance implies growth slightly below the normal market conditions of 4% to 6% [6][7][8] - **2025 Expectations**: If current trends continue, 2025 is expected to approach normal market conditions, with growth driven by the pharmaceutical and biotech sectors [6][7] Market Share and Competitive Position - **Market Share Gains**: Thermo Fisher has consistently gained market share, with expectations to grow 2-3 percentage points faster than the market, leading to long-term growth of 7-9% [9][8] - **Bioproduction Business**: The bioproduction segment is recovering with improved order rates and a strong historical track record. The company remains a market leader in cell culture media and single-use technologies [16][17] - **Analytical Instruments Performance**: The Analytical Instruments segment has shown strong results, particularly in electron microscopy and chromatography, benefiting from high-end research demand [19][20] Strategic Initiatives - **CRO and CDMO Expansion**: The acquisition of PPD and Patheon has strengthened Thermo Fisher's position in the biopharma sector, enhancing its end-to-end capabilities and fostering deep collaboration with customers [24][25] - **Capital Deployment Strategy**: The company plans to continue disciplined capital deployment, focusing on M&A opportunities and returning capital to shareholders through dividends and share buybacks [28][30] Geopolitical Considerations - **U.S.-China Relations**: Ongoing geopolitical tensions may affect operations, but Thermo Fisher aims to support customers in navigating these challenges. The company has a strong presence in the West, which may mitigate reliance on China [14][15] Upcoming Events - **Investor Day**: Scheduled for September 19, 2024, to provide a long-term outlook and insights into business performance [32][33] Key Takeaways - **Resilience in Market Conditions**: Despite challenges, Thermo Fisher is well-positioned for growth, with a strong focus on innovation and customer partnerships [34] - **Focus on Long-term Strategy**: The company emphasizes its commitment to delivering consistent results and maintaining investor confidence [34]

Thermo Fisher Scientific Inc. (NYSE:TMO) Bank of America Securities 2024 Health Care Conference Call May 14, 2024 11:00 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin Thanks everyone for joining us. For those of you who don't know me, my name is Mike Ryskin on BofA life science tools and diagnostics team. And I'm thrilled to kick off the Bank of America Las Vegas Healthcare Conference. Joining us f ...

Have you evaluated the performance of Thermo Fisher Scientific's (TMO) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is ...